PHASE I/II STUDY OF PACLITAXEL CHEMOTHERAPY IN RECURRENT MALIGNANT GLIOMA

这项第二阶段研究的目的是研究该药的有效性。 紫杉醇对小鼠的药效及最大耐受量 治疗复发的恶性胶质瘤患者。所有的病人都会 在紫杉醇注射前使用地塞米松药物预给药， 苯海拉明、雷尼替丁或西咪替丁。这个 药代动力学研究的目标将是确定 紫杉醇每隔3小时输注一次后达到的浓度 直到记录到肿瘤进展的几周或总共12次输液。

The purpose of this Phase II study is to study the effectiveness, side effects & maximum tolerated dose of the drug Paclitaxel (Taxol) in treating patients with recurrent malignant glioma. All patients will be premedicated prior to Taxol infusion using the drugs Dexamethasone, Diphenhydramine & Ranitidine or Cimetidine prior to treatment. The objective of the pharmacokinetics studies will be to determine the concentration of paclitaxel achieved after a 3-hour infusion once every 3 weeks until documented tumor progression or total of 12 infusions.